Tài liệu miễn phí Y khoa - Dược
Download Tài liệu học tập miễn phí Y khoa - Dược
Comprehensive analysis of the autophagydependent ferroptosis-related gene FANCD2 in lung adenocarcinoma
The development of lung adenocarcinoma (LUAD) involves the interactions between cell proliferation and death. Autophagy-dependent ferroptosis, a distinctive cell death process, was implicated in a multitude of diseases, whereas no research revealing the relationship between autophagy-dependent ferroptosis and LUAD pathogenesis was reported.
4/9/2023 11:25:08 PM +00:00
Abundant expression of ferroptosis-related SAT1 is related to unfavorable outcome and immune cell infiltration in low-grade glioma
Low-grade glioma (LGG) is susceptible to ferroptosis, which is involved in TMZ resistance. Ferroptosis induction can enhance the sensitivity to TMZ and synergistically kill glioma cells. T cell-promoted tumor ferroptosis is a vital anti-tumor mechanism of immune checkpoint inhibitors.
4/9/2023 11:25:01 PM +00:00
Prognostic significance of the skeletal muscle index and systemic inflammatory index in patients with lymph node-positive breast cancer after radical mastectomy
The role of skeletal muscle index (SMI) and systemic inflammation index (SII) for patients with lymph node-positive breast cancer remain controversial. This retrospective study aims to evaluate the individual and syner‑ gistic value of SMI and SII in outcomes prediction in this population.
4/9/2023 11:24:55 PM +00:00
Effectiveness of educational intervention on breast cancer knowledge and breast self-examination among female university students in Bangladesh: A pre-post quasi-experimental study
Breast cancer is a global health issue and a leading cause of death among women. Early detection through increased awareness and knowledge on breast cancer and breast cancer screening is thus crucial.
4/9/2023 11:24:45 PM +00:00
Chemotherapy versus chemoradiotherapy for FIGO stages IB1 and IIA1 cervical squamous cancer patients with lymphovascular space invasion: A retrospective study
To evaluate the impact of different adjuvant therapy on IB1 and IIA1 stage cervical squamous cell cancer patients with lymphovascular space invasion. It also aimed to analyze the relationship between lymphovascular space invasion and other clinical pathological characteristics on IB1 and IIA1 stage cervical squamous cell cancer patients.
4/9/2023 11:24:39 PM +00:00
A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: Study protocol
Rectal Cancer is a common malignancy. The current treatment approach for patients with locally advanced rectal cancer involves neoadjuvant chemoradiotherapy followed by surgical resection of the rectum. The resection can lead to complications and long-term consequences.
4/9/2023 11:24:32 PM +00:00
Combination of ferroptosis and pyroptosis to construct a prognostic classifier and predict immune landscape, chemotherapeutic efficacy and immunosuppressive molecules in hepatocellular carcinoma
The induction of ferroptosis and pyroptosis has been highlighted as a novel approach to decide cancer cell fate. However, few studies have systematically explored the role of combining these two novel cell death modalities in hepatocellular carcinoma (HCC).
4/9/2023 11:24:20 PM +00:00
Adverse effects of cell-free and concentrated ascites reinfusion therapy for malignant ascites: A single-institute experience
Cell-free and concentrated ascites reinfusion therapy (CART) is a strategy for improving various intractable symptoms due to refractory ascites, including hypoalbuminemia. CART has recently been applied in the treatment of cancer patients. This study was performed to assess the safety of CART in a single cancer institute.
4/9/2023 11:24:14 PM +00:00
Four differentially expressed genes can predict prognosis and microenvironment immune infiltration in lung cancer: A study based on data from the GEO
Lung cancer is among the major diseases threatening human health. Although the immune response plays an important role in tumor development, its exact mechanisms are unclear.
4/9/2023 11:24:03 PM +00:00
Co-deficiency of B7-H3 and B7-H4 identifies high CD8+T cell infiltration and better prognosis in pancreatic cancer
Immunotherapy is a novel hotspot for the treatment of pancreatic adenocarcinoma (PAAD). However, potential biomarkers which could identify the infamed tumor microenvironment (TME) are urgently required.
4/9/2023 11:23:53 PM +00:00
The survival strength of younger patients in BCLC stage 0-B of hepatocellular carcinoma: Basing on competing risk model
The number of young patients with hepatocellular carcinoma (HCC) is increasing, but whether patients of different ages have a survival advantage is unclear. This study was conducted to investigate whether age differences in the Barcelona Clinic Liver Cancer (BCLC) classification system contribute to the long-term survival outcomes of patients with HCC.
4/9/2023 11:23:46 PM +00:00
A Comprehensive Prognostic Analysis of POLD1 in Hepatocellular Carcinoma
DNA polymerase delta 1 catalytic subunit (POLD1) plays a key role in DNA replication and damage repair. A defective DNA proofreading function caused by POLD1 mutation contributes to carcinogenesis, while POLD1 overexpression predicts poor prognosis in cancers.
4/9/2023 11:23:39 PM +00:00
Sarcopenia as a novel prognostic factor in the patients of primary localized gastrointestinal stromal tumor
Sarcopenia predicts poor prognosis of a variety of gastrointestinal malignancies. However, there is a lack of study on the association between skeletal muscle index (SMI) and the prognosis of gastrointestinal stromal tumor (GIST).
4/9/2023 11:23:33 PM +00:00
Dynamic contrast-enhanced MRI in malignant pleural mesothelioma: Prediction of outcome based on DCE-MRI measurements in patients undergoing cytotoxic chemotherapy
The malignant pleural mesothelioma (MPM) response rate to chemotherapy is low. The identification of imaging biomarkers that could help guide the most effective therapy approach for individual patients is highly desirable.
4/9/2023 11:23:26 PM +00:00
Mammary tumors alter the fecal bacteriome and permit enteric bacterial translocation
Cancer patients experience gastrointestinal and behavioral symptoms, and are at increased risk of systemic infection and inflammation. These conditions are a major source of morbidity and decreased quality of life prior to cancer treatment, but poorly defined etiologies impede successful treatment.
4/9/2023 11:23:18 PM +00:00
No axillary surgical treatment for lymph node-negative patients after ultra-sonography [NAUTILUS]: Protocol of a prospective randomized clinical trial
Following sentinel lymph node biopsy (SLNB), the axillary recurrence rate is very low although SLNB has a false-negative rate of 5–10%. In the ACOSOG Z0011 trial, non-sentinel positive-lymph nodes were found in more than 20% of the axillary dissection group; the SLNB only group did not have a higher axillary recurrence rate.
4/9/2023 11:23:11 PM +00:00
Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: A study protocol for an open-label phase I/ II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma
Cancer-associated fibroblasts (CAFs) are an important component of the tumour microenvironment. Recent studies revealed CAFs are heterogeneous and CAF subset(s) that suppress cancer progression (cancerrestraining CAFs [rCAFs]) must exist in addition to well-characterised cancer-promoting CAFs (pCAFs).
4/9/2023 11:23:04 PM +00:00
Potential efficacy of weekly low-dose administration of bevacizumab as a combination therapy for platinum-resistant ovarian carcinoma: A retrospective analysis
Bevacizumab (Bev) plays the central role of the adjuvant therapy for patients with ovarian carcinoma. The aim of our study was to examine whether differences in the administration of Bev influence the prognosis of patients.
4/9/2023 11:22:55 PM +00:00
Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: A randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma
AGITG DOCTOR was a randomised phase 2 trial of pre-operative cisplatin, 5 fluorouracil (CF) followed by docetaxel (D) with or without radiotherapy (RT) based on poor early response to CF, detected via PET, for resect‑ able oesophageal adenocarcinoma. This study describes PROs over 2 years.
4/9/2023 11:22:45 PM +00:00
Improved urine DNA methylation panel for early bladder cancer detection
Bladder cancer is one of the most common malignancies but the corresponding diagnostic methods are either invasive or limited in specific and/or sensitivity. This study aimed to develop a urine-based methylation panel for bladder cancer detection by improving published panels and validate performance of the new panel with clinical samples.
4/9/2023 11:22:34 PM +00:00
Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model
Both modified FOLFIRINOX (mFFX) and gemcitabine/nab-paclitaxel chemotherapy regimens have been shown to improve clinical outcomes in patients with pancreatic cancer, and are often used interchangeably as the standard of care.
4/9/2023 11:22:27 PM +00:00
The Kaiser Permanente Research Bank Cancer Cohort: A collaborative resource to improve cancer care and survivorship
The Kaiser Permanente Research Bank (KPRB) is collecting biospecimens and surveys linked to electronic health records (EHR) from approximately 400,000 adult KP members. Within the KPRB, we developed a Cancer Cohort to address issues related to cancer survival, and to understand how genetic, lifestyle and environmental factors impact cancer treatment, treatment sequelae, and prognosis.
4/9/2023 11:22:20 PM +00:00
Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease defined using a number of wellestablished molecular subsets. Application of non-negative matrix factorization (NMF) to whole exome sequence data has previously been used to identify six distinct molecular clusters in DLBCL with potential clinical relevance.
4/9/2023 11:22:13 PM +00:00
Body size in early life and the risk of postmenopausal breast cancer
Greater early life adiposity has been reported to reduce postmenopausal breast cancer risk but it is unclear whether this association varies by tumour characteristics. We aimed to assess associations of early life body size with postmenopausal breast cancer and its subtypes, allowing for body size at other ages.
4/9/2023 11:22:06 PM +00:00
Prognostic significance of KLF4 in solid tumours: An updated meta-analysis
Kruppel-like factor 4 (KLF4) is a zinc finger-containing transcription factor predominantly expressed in terminally differentiated epithelial tissues. Many studies have shown that KLF4 has various mechanisms in different tumours; however, the prognostic role of KLF4 remains unclear.
4/9/2023 11:21:58 PM +00:00
Serotoninergic receptor ligands improve Tamoxifen effectiveness on breast cancer cells
Serotonin (or 5-Hydroxytryptamine, 5-HT) signals in mammary gland becomes dysregulated in cancer, also contributing to proliferation, metastasis, and angiogenesis. Thus, the discovery of novel compounds targeting serotonin signalling may contribute to tailor new therapeutic strategies usable in combination with endocrine therapies.
4/9/2023 11:21:46 PM +00:00
Prognostic utility of systemic inflammatory markers and chronic hepatitis C virus infection status in hepatocellular carcinoma patients treated with local ablation
Hepatocellular carcinoma (HCC) has high incidence and mortality worldwide. Local ablation using radiofrequency ablation (RFA) or microwave ablation (MWA) is potentially curative for early-stage HCC with outcomes comparable to surgical resection. We explored the influence of demographic, clinical, and laboratory factors on outcomes of HCC patients receiving ablation.
4/9/2023 11:21:40 PM +00:00
MiR-509-3p is oncogenic, targets the tumor suppressor PHLPP2, and functions as a novel tumor adjacent normal tissue based prognostic biomarker in colorectal cancer
Recently the role of microRNAs has been explored immensely as novel regulators and potential biomarkers in several cancers. MiR-509-3p is one such miRNA that has been observed to show a mixed expression in different cancers, while it’s expression and clinical relevance in colorectal cancer (CRC) has not yet been characterized.
4/9/2023 11:21:33 PM +00:00
A new risk model based on a 11-m6 A-related lncRNA signature for predicting prognosis and monitoring immunotherapy for gastric cancer
N6 -methyladenosine (m6 A) mRNA modification triggers malignant behaviors of tumor cells and thereby drives malignant progression in gastric cancer (GC). However, data regarding the prognostic values of m6 A RNA methylation-related long non-coding RNAs (lncRNAs) in GC are very limited in the literature.
4/9/2023 11:21:22 PM +00:00
Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: A retrospective cohort study
Five-fluorouracil, folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) regimen is used as the first-line treatment for metastatic colorectal cancer (mCRC). The use of capecitabine, an oral fluoropyrimidine pro-drug, is feasible and safe; hence, it provides an interesting alternative to 5-fluorouracil in the abovementioned regimen.
4/9/2023 11:21:10 PM +00:00